Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants.
Barry S Rodgers-GrayJohn R FullartonXavier Carbonell-EstranyIan P KearyJean-Eric TarrideBosco A PaesPublished in: Journal of medical economics (2023)
54%) and provides another option to guide cost-effective RSV prophylaxis in Canada.